{Reference Type}: Journal Article
{Title}: INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) consensus statement: Imaging recommendations for the management of rhabdomyosarcoma.
{Author}: Schoot RA;van Ewijk R;von Witzleben AA;Kao SC;Merks JHMH;Morosi C;Pace E;Shulkin BL;Ferrari A;von Kalle T;van Rijn RR;Weiss AR;Sparber-Sauer M;Ter Horst SAJ;McCarville MB;
{Journal}: Eur J Radiol
{Volume}: 166
{Issue}: 0
{Year}: 2023 Sep 25
{Factor}: 4.531
{DOI}: 10.1016/j.ejrad.2023.111012
{Abstract}: Rhabdomyosarcoma is the most common soft-tissue neoplasm in the pediatric population. The survival of children with rhabdomyosarcoma has only marginally improved over the past 25 years and remains poor for those with metastatic disease. A significant challenge to advances in treatment of rhabdomyosarcoma is the relative rarity of this disease, necessitating years to complete clinical trials. Progress can be accelerated by international cooperation and sharing national experiences. This necessitates agreement on a common language to describe patient cohorts and consensus standards to guide diagnosis, treatment, and response assessment. These goals formed the premise for creating the INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) in 2017. Multidisciplinary members of this consortium have since developed international consensus statements on the diagnosis, treatment, and management of pediatric soft-tissue sarcomas. Herein, members of the INSTRuCT Diagnostic Imaging Working Group present international consensus recommendations for imaging of patients with rhabdomyosarcoma at diagnosis, at staging, and during and after completion of therapy. The intent is to promote a standardized imaging approach to pediatric patients with this malignancy to create more-reliable comparisons of results of clinical trials internationally, thereby accelerating progress in managing rhabdomyosarcoma and improving survival.